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Abstract
Background: Diet is an important environmental factor that interacts with genes to modulate the likelihood of
developing disorders in lipid metabolism and the relationship between diet and genes in the presence of other
chronic diseases such as obesity. The objective of this study was to analyze the interaction of a high fat diet with the
APOA2 (rs3813627 and rs5082), APOA5 (rs662799 and rs3135506) and LEPR (rs8179183 and rs1137101) polymorphisms
and its relationship with obesity and dyslipidemia in young subjects.
Methods: The study included 200 young subjects aged 18 to 25 years (100 normal-weight and 100 obese subjects).
Dietary fat intake was measured using the frequency food consumption questionnaire. Genotyping of polymorphisms
was performed by PCR-RFLP.
Results: Individuals carrying the APOA5 56 G/G genotype with a high saturated fatty acid consumption (OR = 2.7,
p = 0.006) and/or total fat (OR = 2.4, p = 0.018), associated with an increased risk of obesity. We also found that A/G +
G/G genotypes of the 668 A/G polymorphism in the LEPR gene with an intake ≥12 g/d of saturated fatty acids, have
2.9 times higher risk of obesity (p = 0.002), 3.8 times higher risk of hypercholesterolemia (p = 0.002) and 2.4 times higher
risk of hypertriglyceridemia (p = 0.02), than those with an intake <12 g/d of saturated fatty acids. Similarly, LEPR 668 A/
G + G/G carriers with a high fat total intake had 3.0 times higher risk of obesity (p = 0.002) and 4.1 times higher risk of
hypercholesterolemia (p = 0.001).
Conclusion: Our results suggest that dietary fat intake modifies the effect of APOA5 and LEPR polymorphisms on serum
triglycerides, cholesterol levels and obesity in young subjects.
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Background
Genetic variants associated with common polygenic
obesity and dyslipidemias have been reported; unfor-
tunately, many of these associations have been difficult to
replicate [1, 2]. One hypothesis that may account for this
inconsistency is that unexamined factors may modulate
the existence of gene-environment interactions [3, 4]. Diet
is one of the most important environmental factors that
interacts with the genome to modulate disease risk. A bet-
ter understanding of these interactions has the potential
to support disease prevention via modification of dietary
recommendations [5].
In the field of nutritional genetics (nutrigenetics),
researchers study gene—diet interactions in an effort
to better understand factors mediating individual re-
sponse to dietary interventions [6]. Increasing energy
intake is a major contributor to the current obesity
epidemic. Data from the World Health Organization/
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Food and Agriculture Organization (WHO/FAO) showed
that energy intake increased worldwide in about 450 kcal/
person/day, and more than 600 kcal/person/day in devel-
oping countries from the mid-1960s to the late 1990s [7].
However, there are many other factors such as age, sex,
physical activity, alcohol and smoking as well as genetic
factors that will help identify vulnerable populations or in-
dividuals that will benefit from a variety of more personal-
ized and mechanistic-based dietary recommendations [8].
Among the genes involved in the development of obes-
ity and/or dyslipidemia are LEPR, APOA2 and APOA5.
Mutation of the LEPR gene results in leptin insensitivity,
hyperphagia, morbid obesity, including metabolic and
endocrine abnormalities [9]. APOA5 (protein) is regarded
as an important modulator in the metabolism of triglycer-
ides and in plasma it is associated with chylomicrons, very
low density and high density lipoproteins [10]. In associ-
ation studies, polymorphic variants in the gene have been
associated with increased risk of obesity and metabolic
syndrome [11, 12]. APOA2 is the second most common
protein in high-density lipoproteins due to its involvement
in lipid metabolism, as well as in the regulation of food in-
take [13, 14].
The aim of this study was to determine the interaction
of dietary fat intake with the APOA2 (rs3813627 and
rs5082), APOA5 (rs662799 and rs3135506) and LEPR
(rs8179183 and rs1137101) polymorphisms and its rela-
tionship with obesity and dyslipidemia in young subjects.
Results
Anthropometric, biochemical and nutritional
characteristics
The total population for this study included 200 young
subjects, 116 (58 %) were women and 84 (42 %) men
and no significant differences were observed for age and
gender. General characteristics of all subjects by group
are shown in Table 1. Obese subjects had significantly
elevated clinical and biochemical measures and lower
HDL-cholesterol levels (all P < 0.05) than normal-weight
controls. The evaluation of the dietary nutritional intake
showed that obese group had a higher calorie and
macronutrient consumption expressed in grams/day (g/
d) than the control group but no differences were ob-
served in cholesterol consumption (mg/d) (Table 1).
Genotypic and allele frequencies
All polymorphisms in this study were in Hardy Weinberg
Equilibrium in the control group: (χ2 = 0.01, P = 0.91 668A/
G and χ2 = 2.6, P = 0.10 1968G/C in LEPR gene; χ2 = 0.27,
P = 0.60 -1131 T/C and χ2 = 0.67, P = 0.41 56 C/G in
APOA5 gene, and χ2 = 1.35, P = 0.24 -265 T/C in APOA2
gene). The APOA2 -1730 G/T polymorphism was mono-
morphic for the wild allele. No significant differences in the
frequencies of genotypes or alleles between groups were ob-
served (Table 2).
Clinical, biochemical and nutritional characteristics
according to APOA2, APOA5 and LEPR polymorphisms
The analysis of the clinical, biochemical and nutritional
characteristics by genotypes in all subjects showed that
the APOA2 -265 T/T genotype carriers had a higher in-
take of polyunsaturated fatty acids (P = 0.02) than the T/
C + C/C carriers. Furthermore, we found that the carriers
of the T/C +C/C genotypes for the APOA5 -1131 T/C
polymorphism had decreased levels of HDL-cholesterol
(P = 0.02) and an increased intake of polyunsaturated
fatty acids (P = 0.037) compared with the T/T genotype
(Table 3).
In addition, the LEPR 668 A/G +G/G genotypes showed
increased serum levels of LDL-cholesterol (P = 0.02) than
those with the A/A genotype (Table 3). Serum lipid levels
and dietary nutritional intake were not associated with
APOA5 56 C/G and LEPR 1968 G/C polymorphisms in all
subjects (data not shown).
Gene-diet interactions for obesity and/or dyslipidemia
To estimate the association between consumption of satu-
rated fatty acids and/or lipids with the presence of obesity
and dyslipidemia we used logistic regression models ad-
justed for age, gender and physical activity; the results are
given in Table 4. We found that risk of obesity and dyslip-
idemia was higher in individuals who had an increased
intake of saturated fatty acids ≥12 g/d (OR = 3.9, 95 % CI
2.0–7.6; P < 0.001) and/or total fat ≥83 g/d (OR = 3.8, 95 %
CI 1.9–7.7; P < 0.001).
Similarly, we found that for polymorphism 668 A/G of
the LEPR gene, the G allele carriers had 2 times higher
risk of total cholesterol levels ≥200 mg/dL (OR = 2.1,
95 % CI 1.15–3.8; P = 0.008, data not shown), but when
the analysis was performed by genotypes, we found that
the AG +GG carriers had a high risk of hypercholester-
olemia (OR = 9.4, 95 % CI 2.1–41.5; P = 0.003, Table 4).
The risk of obesity and/or dyslipidemia associated with
dietary fatty acid intake of subjects according to APOA2,
APOA5 and LEPR genes are presented in Table 4. Individ-
uals carrying the APOA5 56 G/G genotype with a high
saturated fatty acid consumption ≥12 g/d (OR = 2.7, 95 %
CI 1.3–5.6; P = 0.006) and/or total fat ≥83 g/d (OR = 2.4,
95 % CI 1.2–4.9; P = 0.018) were associated with an in-
creased risk of obesity.
This analysis revealed that A/G + G/G genotypes of
the 668 A/G polymorphism in the LEPR gene with an
intake ≥12 g/d of saturated fatty acids, have 2.9 times
higher risk of obesity (P = 0.002), 3.8 times higher risk of
cholesterol levels ≥200 mg/dL (P = 0.002) and 2.4 times
higher risk of triglyceride levels ≥150 mg/dL (P = 0.02),
than those with an intake <12 g/d of saturated fatty acids.
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Similarly, LEPR 668 A/G + G/G carriers with a high
fat total intake had 3.0 times higher risk of obesity
(P = 0.002) and 4.1 times higher risk of cholesterol
levels ≥200 mg/dL (P = 0.001) than those with a low
intake of total fat <83 g/d.
Discussion
Obesity is characterized by an energy imbalance between
calories consumed and expended also known to be asso-
ciated with cardiovascular risk factors such as dyslipid-
emia [15]. Dietary intake is associated with multiple
health outcomes and is one of the critical, potentially
modifiable environmental exposures to consider in gene-
environment studies related with obesity [16].
In this study we found a gene-diet interaction for the
668 A/G polymorphism in the LEPR gene and 56 C/G in
the APOA5 gene with a high intake of saturated fatty
acids (SFA) and total fat was associated with obesity,
hypercholesterolemia and hypertriglyceridemia.
Differences have been reported in dietary intake be-
tween normal-weight and obese subjects. Our results are
consistent with previous findings, where obese subjects
have a higher intake in total energy, carbohydrates, total
fat and protein as well as saturated, monounsaturated and
polyunsaturated fatty acids, but no significant differences
Table 1 Clinical, biochemical and nutritional variables between groups
Variables Total Control group Obese group P
n = 200 n = 100 n = 100
Clinical
Age (years)a 20.9 ± 1.9 20.7 ± 1.9 21.2 ± 1.8 0.05
Sexb Women 116 (58) 65 (65) 51 (51) 0.05
Men 84 (42) 35 (35) 49 (49)
Weight (kg)c 70.7 (56.5–91.5) 56.5 (51.1–91.5) 91.5 (82.4–99.6) <0.001
Height (cm)a 162.7 ± 9.1 160.9 ± 8.9 164.5 ± 9 0.005
BMI (kg/m2)c 27.4 (21.5–33.1) 21.5 (20.3–23) 33.1 (31.4–35.3) <0.001
Waist circumference (cm)c 88.3 (78–106) 78 (74.1–82) 106 (100.4–110.3) <0.001
Hip circumference (cm)c 101 (92–115) 92 (88.5–110) 115 (110–119.3) <0.001
Fat mass (g)c 23.3 (10.3–32.9) 10.3 (7.6–14.3) 32.9 (28.8–38.7) <0.001
Fat percentage (%)c 28.4 (18.4–37.4) 18.5 (13.9–24.9) 37.4 (32.1–42.3) <0.001
SBP (mmHg)a 109.8 ± 12.8 102.8 ± 9.8 116.9 ± 11.4 <0.001
DBP (mmHg)c 69 (63.5–76) 66 (60–71.5) 73 (67.5–80) <0.001
Biochemical
Glucose (mg/dL)c 83 (76–89) 80 (74–85) 85.5 (79–93) <0.001
Total cholesterol (mg/dL)c 159.5 (141.5–181.5) 149.5 (132–176) 167.5 (148.5–192) 0.002
LDL-C (mg/dL)c 108 (85.5–130.5) 95.5 (81.5–119) 114 (88.5–146) <0.001
Triglycerides (mg/dL)c 96 (69.5–144.5) 78 (60–103) 121 (91–165.5) <0.001
HDL-C (mg/dL)c 44 (37–52.5) 47 (38–55) 42.5 (36–47.5) 0.005
Nutritional
Total energy (kcal/d)c 2424.5 (2064–2835) 2184.5 (1902.5–2478.5) 2659.5 (2342.5–3063.5) <0.001
Carbohydrates (g/d)c 318 (272.8–382.5) 298.5 (256.5–331.5) 350.5 (301.5–434) <0.001
Protein (g/d)c 103 (85–125.5) 94.5 (78–113.5) 117.6 (96–140) <0.001
Total fat (g/d)c 79 (61.5–96.7) 69.5 (58–86.5) 88.5 (73.5–103) <0.001
SFA (g/d)c 11 (8–15) 9.5 (6–13) 13 (10–18) <0.001
MUFA (g/d)c 17 (13–23) 15 (10.5–20) 20.5 (15–27) <0.001
PUFA (g/d)c 9 (6–12) 7 (5–9) 11 (8–15) <0.001
Cholesterol (mg/d)c 263.5 (171–341) 263.5 (188–330) 264 (168–35) 0.69
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, LDL low-density lipoprotein cholesterol, HDL high-density lipoprotein cholesterol,
SFA saturated fatty acids, MUFA monounsaturated fatty acids, PUFA polyunsaturated fatty acids
aData provided in Mean ± SD; Student t test
bData provided in n and percentage; Chi-square test
cData provided in Median (percentile 25–75); Mann Whitney test
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in cholesterol intake were observed, which explains excess
body weight as a result of the high consumption of energy
from macronutrients and in addition, fatty acids induce
excess lipid accumulation in obese subjects. Furthermore,
the obese group had increased lipid levels and low HDL-
cholesterol levels, which are traditional cardiovascular risk
factors associated with the high consumption of total fat
and augmented adiposity [17].
Since the obese group had a high intake of macronu-
trients and total fat, suggests that consuming a high-fat
diet has not effect on the satiety. However, whether fatty
acid saturation differentially modulates satiety or energy
intake is unclear. Maljaars and colleagues conducted a
study in which fat emulsions were infused into the small
intestine of 15 healthy subjects and found that triacyl-
glycerol composed of unsaturated fatty acids (C18:2 and
C18:1) significantly increased satiety and cholecystokinin
secretion compared with the control group, without al-
tering food intake, whereas those composed of saturated
fatty acids (C18:0) had no effect [18]. Animal studies
have established that ad libitum access to a high-fat diet
promotes hyperphagia and obesity and is associated with
leptin and insulin resistance [19]. The lack of consistency
between measures of satiety/appetite and fat intake does
not provide clarity on the role of saturated fat intake in
the modulation of the satiety.
The frequency of the G allele polymorphism 56 C/G
was higher in our population unlike other populations
[20, 21]. The importance of this finding relies upon the
association with obesity and intake of fatty foods found
in this study, suggesting its role as an important risk
factor for developing obesity in our population due to its
high frequency.
Regarding the polymorphism 668 A/G in the LEPR
gene, the G allele was found in 44 % of our population,
but our results demonstrate discordance with those pub-
lished in other populations [22, 23], as well as for other
variants analyzed in this study. For this finding, we
must point out that Mexican population is a mixture of
Amerindian and European ancestry with a small pro-
portion of African ancestry, however, the distribution
can vary even within each region, which can also interfere
with frequencies found in different populations [24].
Table 2 Genotypic and allele frequencies between groups
Gene/
polymorphisms
Genotype Cases Controls P
n (%) n = 100 n = 100
LEPR
rs1137101
A/A 63 (31.5) 33 (33) 30 (30)
A/G 96 (48) 46 (46) 50 (50) 0.84c
G/G 41 (20.5) 21 (21) 20 (20)
Allele
A 222 (0.56) 112 (0.56) 110 (0.55) 0.84b
G 178 (0.44) 88 (0.44) 90 (0.45)
rs8179183
G/G 137 (68.5) 65 (65) 72 (72)
G/C 59 (29.5) 31 (31) 28 (28) 0.10a
C/C 4 (2) 4 (4) 0 (0)
Allele
G 333 (0.83) 161 (0.80) 172 (0.86) 0.14b
C 67 (0.17) 39 (0.20) 28 (0.14)
APOA5
rs662799
T/T 139 (69.5) 70 (70) 69 (69)
T/C 59 (29.5) 30 (30) 29 (29) 0.60a
C/C 2 (1) 0 (0) 2 (2)
Allele
T 337 (0.84) 170 (0.85) 167 (0.84) 0.68b
C 63 (0.16) 30 (0.15) 33 (0.16)
rs3135506
C/C 11 (5.5) 4 (4) 7 (7)
C/G 72 (36) 39 (39) 33 (33) 0.53a
G/G 117 (58.5) 57 (57) 60 (60)
Allele
C 94 (0.24) 47 (0.24) 47 (0.24) 1.0b
G 306 (0.76) 153 (0.76) 153 (0.76)
APOA2
rs5082
T/T 143 (71.5) 74 (74) 69 (69) 0.56a
T/C 54 (27) 24 (24) 30 (30)
C/C 3 (1.5) 2 (2) 1 (1)
Allele
T 340 (0.85) 172 (0.86) 168 (0.84) 0.57b
C 60 (0.15) 28 (0.14) 32 (0.16)
rs3813627
G/G 200 (100) 100 100
G/T - - - -
T/T - - -
Table 2 Genotypic and allele frequencies between groups
(Continued)
Allele
G 400 (1.0) 200 (1.0) 200 (1.0) -
T - - -
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Table 3 Clinical, biochemical and nutritional variables according to polymorphisms in APOA5, LEPR and APOA2 genes
Variables Polymorphism −1131 T/C in the gene APOA5 P Polymorphism −265 T/C in the gene APOA2 P Polymorphism 668 A/G in the gene LEPR P
T/T T/C + C/C T/T T/C + C/C A/A A/G + G/G
n = 139 (69.5) n = 61 (30.5) n = 143 (71.5) n = 57 (28.5) n = 63 (31.5) n = 137 (68.5)
Clinical
Age (years)b 21 (20–22) 20 (19–22) 0.47 21 (19–22) 21 (20–22) 0.98 21 (20–23) 21 (19–22) 0.72
Weight (kg)b 74.3 (55.5–91.8) 69.5 (58.4–88.8) 0.76 74.3 (56.9–93.2) 68.2 (55.3–89.2) 0.80 75.7 (56.1–93.4) 69.5 (56.9–90.4) 0.94
BMI (kg/m2)b 30 (21.3–33.2) 24.4 (22–32.2) 0.72 30 (21.5–33) 24.1 (21.4–33.1) 0.62 30.7 (21.3–33.2) 24.7 (21.7–33) 0.92
Waist (cm)b 89 (78–106) 87 (79–105.8) 0.85 91.5 (79–106) 86 (77–102.5) 0.29 90 (78–106.5) 88.2 (78–104) 0.88
SBP (mmHg)a 109.3 ± 12.7 111.1 ± 12.9 0.35 110 ± 12.5 109.4 ± 13.6 0.77 108.4 ± 11.4 110.5 ± 13.4 0.28
DBP (mmHg)b 69 (64–75) 69 (63–76) 0.89 69 (63–76) 70 (64–74) 0.99 69 (63–76) 70 (64–75) 0.49
Biochemical
Glucose (mg/dL)b 84 (76–89) 82 (74–88) 0.34 83 (76–89) 83 (78–89) 0.54 84 (76–89) 83 (76–89) 0.70
Cholesterol (mg/dL)b 160 (143–185) 150 (136–177) 0.14 160 (141–182) 157 (142–179) 0.67 153 (142–171) 162 (141–191) 0.07
LDL-C (mg/dL)b 109 (87–132) 106 (84–125) 0.57 110 (83–130) 106 (88–131) 0.99 103 (75–119) 111 (88–138) 0.02
Triglycerides (mg/dL) 94 (69–144) 104 (74–145) 0.32 94 (70–151) 98 (63–121) 0.32 93 (63–129) 100 (73–148) 0.19
HDL-C (mg/dL)b 45 (38–54) 41 (35–48) 0.02 44 (37–51) 45 (37–53) 0.95 43 (37–51) 45 (37–53) 0.50
Nutritional
Total energy (kcal/d)b 2440 (2049–2860) 2411 (2179–2724) 0.79 2427 (2054–2854) 2411 (2130–2822) 0.86 2452 (2130–2764) 2418 (2022–2854) 0.72
Carbohydrates (g/d)b 318 (270.8–390) 318 (276–370) 0.87 318 (277–380) 320 (264–391) 0.74 318 (278–380) 318 (270–391) 0.89
Protein (g/d)b 105 (84–127) 100 (85–118.2) 0.56 101 (83–126) 107 (89–125) 0.63 108 (86.9–123) 101 (83–126) 0.46
Total fat (g/d)b 81 (61–98) 77 (65–95) 0.58 78 (62–96.5) 84 (61–97) 0.98 80 (65–97) 79 (61–96.5) 0.69
SFA (g/d)b 11 (8–16) 11 (8–15) 0.45 11 (9–15) 10 (7–15) 0.27 11 (8–14) 11 (8–16) 0.97
MUFA (g/d)b 17 (13–24) 16 (12–21) 0.18 17 (13–23) 16 (12–23) 0.23 17 (13–23) 17 (13–23) 0.86
PUFA (g/d)b 8 (6–12) 10 (8–12) 0.037 9 (7–13) 8 (6–10) 0.02 9 (7–12) 9 (6–12) 0.61
Cholesterol (mg/d)b 258 (172–359) 273 (152–329) 0.91 275 (186–345) 245 (143–328) 0.26 261 (143–329) 267 (181–357) 0.56
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, LDL low-density lipoprotein cholesterol, HDL high-density lipoprotein cholesterol, SFA saturated fatty acids, MUFA monounsaturated fatty
acids, PUFA polyunsaturated fatty acids
aData provided in Mean ± SD; Student t test

















Although a number of genes are associated with either
weight or obesity and dyslipidemias, few have been
shown to interact with diet and contribute to obesity
and comorbidities. In this study, the APOA5 -1131 T/C
+ C/C genotypes were associated with decreased levels
of HDL-cholesterol and a high intake of polyunsaturated
fatty acids (PUFA). Apolipoprotein A5 is found almost
exclusively in association with lipoproteins as HDL, VLDL
and chylomicrons [25]. In addition, the −1131 T/C poly-
morphism has been associated with low levels of
APOA5 and therefore we suggest that it may be also be
related with low levels of HDL [26]. Moreover, we
found no gene-diet interactions in triglyceride levels
contrasting with reports in other populations [27, 28],
this could be due to the low risk allele frequency found
in our population (0.16).
A significant interaction between APOA5 56G allele
and high consumption of total fat and saturated fatty
acids (SFA) associated with obesity but not with lipid
levels, was found in this study. The 56 C/G gene variant,
results in a change of serine to tryptophan at codon 19.
Apolipoproteins and other polypeptides are known to
contain N-terminal export signal sequences. Indeed, com-
putational analyses for APOA5 predicted a strong export
consensus sequence with a likely export cleavage site be-
tween amino acids 23 and 24 [29]. The change of a serine
to a tryptophan residue at position 19 could reduce the
rate of APOA5 export from the liver. Van den Berg et al.,
showed that high-fat diet contributes to the development
of obesity and insulin resistance (IR) in APOA5-knockout
mice (APOA5−/−). They also found that peripheral and
central APOA5 protein administration in wild-type mice
Table 4 Interaction between polymorphisms studied with saturated fat intake (≥12 g/d) and total fat (≥83 g/d)
Variables Obesity Cholesterol Triglycerides LDL-C HDL-C
IMC≥ 30 kg/m2 ≥200 mg/dL ≥150 mg/dL ≥100 mg/dL ≤40 mg/dL
OR (95 % CI); Pa
SFA≥ 12 g/d 3.9 (2.0–7.6); <0.001 1.8 (0.8–4.1); 0.15 1.3 (0.7–2.7); 0.4 1.5 (0.8–2.7); 0.2 1.0 (0.6–1.8); 0.9
Total fat≥ 83 g/d 3.8 (1.9–7.7); <0.001 1.7 (0.7–3.9); 0.2 1.0 (0.5–2.2); 0.9 1.3 (0.7–2.4); 0.3 0.9 (0.5–1.8); 0.8
APOA5 gene
Polymorphism −1131 T/C
Genotype T/C + C/C 0.9 (0.5–1.7); 0.7 0.7 (0.3–1.7); 0.4 0.9 (0.4–2); 0.9 0.8 (0.4–1.4); 0.4 1.9 (1.0–3.6); 0.05
Interaction T/C + C/C – SFA (≥12 g/d) 1.4 (0.5–3.5); 0.5 0.5 (0.1–2.2); 0.3 1.4 (0.5–3.8); 0.5 1.0 (0.4–2.5); 0.9 2.1 (0.9–5.0); 0.09
Interaction T/C + C/C – Total fat (≥83 g/d) 0.9 (0.4–2.5); 0.9 0.5 (0.1–2.5); 0.4 1.2 (0.4–3.5); 0.7 1.0 (0.4–2.4); 1.0 1.9 (0.8–4.8); 0.13
Polymorphism 56 C/G
Genotype G/G 0.97 (0.5–1.8); 0.9 0.8 (0.4–1.8); 0.6 0.6 (0.3–1.2); 0.1 0.7 (0.4–1.3); 0.2 0.7 (0.4–1.2); 0.2
Interaction G/G – SFA (≥12 g/d) 2.7 (1.3–5.6); 0.006 0.97 (0.4–2.4); 0.9 1.2 (0.6–2.6); 0.6 0.8 (0.45–1.6); 0.6 0.8 (0.4–1.6); 0.5
Interaction G/G – Total fat (≥83 g/d) 2.4 (1.2–4.9); 0.018 1.1 (0.4–2.6); 0.9 1.0 (0.5–2.3); 0.9 0.7 (0.4–1.4); 0.4 0.8 (0.4–1.5);0.5
LEPR gene
Polymorphism 1968 G/C
Genotype G/C + C/C 1.3 (0.6–2.5); 0.5 0.7 (0.3–1.8); 0.5 0.8 (0.4–1.8); 0.6 0.8 (0.4–1.4); 0.4 0.8 (0.4–1.5); 0.5
Interaction G/C + C/C – SFA (≥12 g/d) 2.2 (0.9–5.3); 0.07 0.5 (0.1–1.9); 0.3 0.9 (0.4–2.4); 0.9 1.2 (0.5–2.7); 0.6 0.7 (0.3–1.7); 0.5
Interaction G/C + C/C – Total fat (≥83 g/d) 2.5 (1.0–6.2); 0.05 0.9 (0.3–2.8); 0.8 0.8 (0.3–2.2); 0.7 1.6 (0.7–3.7); 0.3 0.6 (0.2–1.3); 0.2
Polymorphism 668 A/G
Genotype A/G + G/G 1.1 (0.6–2.1); 0.7 9.4 (2.1–41.5); 0.003 1.8 (0.8–3.9); 0.2 1.5 (0.8–2.8); 0.2 0.9 (0.5–1.7); 0.7
Interaction A/G + G/G – SFA (≥12 g/d) 2.9 (1.5–5.8); 0.002 3.8 (1.6–8.5); 0.002 2.4 (1.2–4.9); 0.02 1.9 (1.0–3.6); 0.05 1.3 (0.7–2.4); 0.4
Interaction A/G + G/G – Total fat (≥83 g/d) 3.0 (1.5–6.2); 0.002 4.1 (1.8–9.6); 0.001 1.6 (0.8–3.4); 0.2 1.6 (0.8–3.2); 0.14 1.3 (0.7–2.5); 0.4
APOA2 gene
Polymorphism −265 T/C
Genotype T/C + C/C 0.7 (0.4–1.4); 0.3 0.9 (0.4–2.4); 0.9 0.5 (0.2–1.2); 0.1 0.8 (0.4–1.5); 0.5 1.0 (0.5–1.9); 0.9
Interaction T/C + C/C – SFA (≥12 g/d) 2.2 (0.8–5.6); 0.1 1.2 (0.4–3.9); 0.7 0.4 (0.1–1.6); 0.2 1.6 (0.6–3.9); 0.3 1.4 (0.6–1.2); 0.4
Interaction T/C + C/C – Total fat (≥83 g/d) 1.3 (0.6–3.1); 0.5 0.6 (0.2–2.2); 0.5 0.3 (0.08–1.1); 0.07 0.6 (0.3–1.4); 0.3 1.4 (0.6–3.1); 0.4
OR odds ratio, CI confidence interval, SFA saturated fatty acids; Reference category is genotype with major and/or minor frequency with low intake total fat and/or
SFA, SFA saturated fatty acids, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol
aOR adjusted by sex, age and physical activity
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significantly reduced their food intake compared with
APOA5 −/− mice. They suggest that low-circulating levels
of APOA5 protein seen in rodents and humans may sug-
gest a satiety-related signaling function, in addition to an
effect of APOA5 on triglyceride hydrolysis [30].
Our study also found that LEPR 668G allele carriers
have an increased risk of hypercholesterolemia, also the
interaction of allele with high-fat diet promotes hyper-
cholesterolemia, hypertriglyceridemia and obesity. Leptin
generates its central and peripheral effects by binding to
its receptors on the cell surface and subsequently activat-
ing downstream signaling pathways. Through posttran-
scriptional alternative RNA splicing, several isoforms of
leptin receptors with identical extracellular and trans-
membrane domains but variable intracellular domains are
expressed in humans [31]. Leptin binds to the long form
of leptin receptor (LEPR) of multiple neuronal populations
activating the JAK2/STAT3 pathway to regulate the syn-
thesis of different neuropeptides implicated in the control
of food intake and energy balance [32]. It has also been
found that mutations of the LEPR gene results in leptin
insensitivity, hyperphagia, morbid obesity, as well as meta-
bolic and endocrine abnormalities [33].
The 668 A/G polymorphism includes a change of A to
G in the leptin receptor gene, which is located in exon 6
encoding the extracellular region of the gene at nucleotide
position 668, and confers an amino acid change at codon
223 (Q223R) changing the charge from a neutral amino
acid (glutamine) to a positive (arginine) affecting receptor
binding to its ligand [34]. However, we must point out
that this is not the only polymorphism in this region of
the gene, which may act in combination with other poly-
morphisms and non-genetic factors such as exercise,
thereby contributing to what is known as leptin resistance,
and thus, increasing the obesity phenotype. Furthermore,
we observed that the lipolysis stimulator receptor (LSR) is
actively involved in the regulation of postprandial lipemia.
Based on the results found by Stenger et al. where they
propose that the presence of leptin is important to main-
tain optimal levels of protein LSR in order to ensure effi-
ciency of lipid metabolism during the postprandial phase,
this can be complementary to its action as a satiety factor.
However if leptin signaling is defective in the liver,
this may induce suboptimal levels of protein expres-
sion of the LSR, which may contribute to elevated
postprandial lipemia. This promotes increased lipemia
in peripheral tissues, mainly in adipose tissue. As a result,
it been proposed that leptin modulates LSR which pro-
motes lipid removal during the postprandial phase and
can contribute to the dynamics of the distribution and
utilization of lipids in different tissues [35].
Our study also found that APOA2 -265 T/T carriers
had a greater consumption of polyunsaturated fatty
acids (PUFA) unlike with the genotype T/C + C/C, but
another study in individuals with European ancestry
and genotype C/C, had an increased BMI and a high
intake of total energy [36], this difference could be at-
tributed to the sample size used in the study, which
was comprised of 514 men and 564 women and found
a greater number of C allele carriers. The APOA2 gene
is a member of the superfamily of apolipoproteins
which include gene encoding soluble proteins such as
APOA1 and APOA4 that share its genome structure
and several functions. APOA4 has been associated with
the regulation of food intake, satiety signal acting as
well as APOA2 may be involved in the regulation of
food intake [37].
Nonetheless, we did not find interactions between
APOA2 -265 T/C and APOA5 -1131 T/C and dietary
fat intake associated with obesity or serum lipid levels
compared to other studies in Mediterranean, Asian and
American populations [38–40]. These differences are
supported by various reasons: first, the minor allele fre-
quencies were low in our population (1.5 % for −265 T/
C and 1 % for −1131 T/C polymorphisms), due to the
small sample size; second, subject characteristics such
as ethnicity, health status and other environmental and
genetic factors are different; finally, our population pre-
sented different dietary patterns compared to other
populations. However, future studies involving larger
sample sizes are needed to confirm these findings.
Conclusions
Our results suggest that dietary fat intake modifies the
effect of polymorphisms at the APOA5 and LEPR genes
on serum triglycerides, cholesterol levels and obesity in
young subjects. This gene-nutrient interaction could
help to explain in Mexican subjects the variations in the
lipid profile in response to fat intake, however, further
studies are needed to confirm these findings.
Methods
Participants and study design
A total of 200 unrelated young subjects were re-
cruited, aged 18 to 25 years old, 100 normal-weight
(BMI 18.5 to 24.9 kg/m2) and 100 with obesity (BMI
≥30 kg/m2). None of the individuals were in treatment
or diet to lose weight and pregnant women were not
included in the study. Informed written consent was
obtained from all participants according to the Declar-
ation of Helsinki. The study was approved by the Research
Ethics Committee of the University of Guerrero (registra-
tion number 012/2013).
Anthropometric and biochemical analysis
Body weight was determined in light clothes and with-
out shoes using a body composition monitor (TFB-300
GS, Tanita Corporation of America Inc USA). Height
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was measured with a stadiometer (BM-214, Seca, Ham-
burg, Germany). From these measurements, the body
mass index was calculated as weight in kilograms divided
by height in meters squared (kg/m2). Body circumferences
were measured using an anthropometric tape (Seca 203,
Hamburg, Germany). Waist circumference was measured
at the umbilicus level and the superior iliac crest; and hip
circumference was measured at the maximum point
below the waist, without compressing the skin. Blood
pressure was measured in the sitting position with an
automatic sphygmomanometer (Omron MX3 Plus) on
the left arm after 10 min rest, and the reading was re-
ported in mmHg.
A fasting blood sample was taken to measure glucose,
total cholesterol, HDL-cholesterol, LDL-cholesterol and
triglycerides levels. Biochemical analysis was performed
with commercially available kits (Spinreact) in semi-
automated equipment Spinlab.
Dietary assessment
Information on food and nutrition was obtained by
means of a food-frequency questionnaire (FFQ), which
was employed for the analysis of dietary data from the
2006 and 2012 ENSANUT Surveys [41]. The person re-
sponsible for data collection was a research dietitian
trained in the methodology. Interviews were conducted
from Monday to Friday. The questionnaire allowed the
assessment in the consumption of food groups, energy,
macronutrients and micronutrients with Nutrimind
software (Mexico). The software contains over 2000
foods and allows the entry of other foods that are not
consumed frequently. These calculations of macronutri-
ents are based on the source tables foods like Mexican
Food System Equivalents 1st and 2nd Edition, USDA
(United States), Argenfoods (Argentina), Peruvian Journal
of Cardiology (July to December 2000) and the table of
food composition from Chile.
Table 5 Sequence of the primers, enzymes and sizes of PCR-RFLP fragments
Polymorphisms Primer sequence Annealing temp. (°C) Product size (bp) Restriction enzyme/allele sizes
GEN LEPR
BstUI
1968 G/C (rs8179183) F 5′-AATCCAGCCTACACAGTTGT-3′ 63 224 G/G 224
R 5′-CTTCCAAAGTAAAGTGACATTTTTCGC-3′ G/C 224, 198, 26
C/C 198, 26
MspI
668 A/G (rs1137101) F 5′-AAACTCAA CGACACTCTC CTT-3′ 63 80 A/A 80




56 C/G (rs3135506) F 5′-CACAGAGGTTGAGGCAGCAGA-3′ 60 335 C/C 151, 77, 40, 35, 31, 1
R 5′-GGCTCTGGCTCTTCTTTCAGG-3′ C/G 186, 151, 77, 40, 35, 31, 1
G/G 186, 77, 40, 31, 1
MseI
−1131 T/C (rs662799) F 5′-GGAGC TTGTGAACGTGTGTATGAGT-3′ 58 187 T/T 157, 30




−265 T/C (rs5082) F 5′-GATAAGGTTGAGAGATGAGATCT-3′ 62 310 T/T 310
R 5′-GTGAGGATAAACAAGTTGGAGAA-3′ T/C 310,167,143
C/C 167,143
NheI
−1730 G/T (rs3813627) F 5′-GAATAGTTCTGCTAGCACTTAC-3′ 64 162 G/G 151, 11
R 5′-CAAATGAGTACTACTCATTAAG-3′ G/T 162, 151, 11
T/T 162
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DNA extraction and genotyping
Genomic DNA was extracted from white blood cells by
the Miller technique and the screening for the APOA2
(−1730 G/T, rs3813627 and −265 T/C, rs5082), APOA5
(−1131 T/C, rs662799 and 56 C/G, rs3135506) and
LEPR (1968 G/C, rs8179183 and 668 A/G, rs1137101)
polymorphisms, were performed by polymerase chain
reaction-restriction fragment length polymorphism
(PCR-RFLP). Primers for the polymorphisms were de-
signed and restriction enzymes were identified using
the Primer 3[42] and NEBcutter software, respectively
[43]. All PCRs were performed in a research thermal
cycler, using Taq polymerase (Invitrogen Life Technolo-
gies). Characteristics of the studied polymorphisms are
presented in Table 5.
For the identification of all polymorphisms, quality
control measures including positive and negative con-
trols as well as replicated samples (10 % at random)
were employed.
Statistical analysis
The information obtained was analyzed in STATA stat-
istical package v.12.0 (College Station, TX). For the
descriptive analysis we obtained means and standard
deviations of symmetric quantitative variables and com-
parison between groups was performed using the stu-
dent t test and/or ANOVA; for the non-symmetric
quantitative variables we obtained median and percentiles
25 and 75 and the comparison between groups was per-
formed using the Mann Whitney and/or Kruskal Wallis.
Absolute and relative frequencies for qualitative variables
were determined and the comparison between the study
groups (normal-weight vs. obese subjects) was performed
using the Chi square test statistic (X2). The genotype and
allele frequencies for the analyzed polymorphisms were
performed by direct counting and Hardy-Weinberg equi-
librium in the control group was calculated. Dietary fat
intake was analyzed as both continuous and categorical
variables, dichotomized by the population mean as a cut-
off point. Two categories of saturated fat intake (<12
and ≥12 g/d) and total fat intake (<83 and ≥83 g/d)
were considered. Logistic regression models, adjusted
and unadjusted, were constructed to assess the associ-
ation between the SNPs of the LEPR, APOA2 and
APOA5 genes with a high dietary fat intake and deter-
mination of OR for the presence of obesity and dyslip-
idemia. P-values <0.05 were considered statistically
significant.
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